Japan To Fast-Track Foreign-Approved Orphan Drugs
This article was originally published in PharmAsia News
Japan's Health Ministry has earmarked extra funds in its budget this year to speed its approval process for foreign-approved drugs, including creation of a fast-track system. The funding request includes subsidies to drug makers and others to share some of the costs of clinical trials for drugs intended for children and for treating cancer. The plans call for approving fast-tracked drugs in six months and adding staff to the Pharmaceuticals and Medical Devices Agency for product reviews. The new, faster procedure is to be available for about 50 drugs on a list yet to be compiled, primarily orphan drugs. (Click here for more - a subscription may be required
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.